Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Glutathione. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.69 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.69 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.51 |
| ▸ | LTA4H | P09960 | 4/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MB | P02144 | 1/20 | 0.39 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RARG | P13631 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glutathione SCHEMBL18284974 | 1.00 | PTGS1 (0.69) | PTGS1GSTK1GLO1LTA4HOPRD1 | |
| SCHEMBL1133901 | 0.85 | PTGS1 (0.57) | PTGS1GSTK1GLO1LTA4HMEN1 | |
| SCHEMBL1133983 | 0.85 | PTGS1 (0.57) | PTGS1GSTK1GLO1LTA4HOPRK1 | |
| Glutathione SCHEMBL8215210 | 0.84 | PTGS1 (0.92) | PTGS1GSTK1GLO1 | |
| Glutathione SCHEMBL20298530 | 0.84 | PTGS1 (0.92) | PTGS1GSTK1GLO1 | |
| Glutathione SCHEMBL20298529 | 0.84 | PTGS1 (0.92) | PTGS1GSTK1GLO1 | |
| Glutathione SCHEMBL8215201 | 0.84 | PTGS1 (0.92) | PTGS1GSTK1GLO1 | |
| Glutathione SCHEMBL28212822 | 0.83 | PTGS1 (0.90) | PTGS1GSTK1GLO1 | |
| Glutathione SCHEMBL3790504 | 0.83 | PTGS1 (0.95) | PTGS1GSTK1GLO1 | |
| Glutathione SCHEMBL3790499 | 0.83 | PTGS1 (0.95) | PTGS1GSTK1GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113677706-B | Treatment of liver toxicity | 新加坡保健服务私人有限公司 | 2025-05-02 | — | — | CN | disclosed |
| US-20230139291-A1 | EXPANSION AND MAINTENANCE OF ADULT PRIMARY HUMAN HEPATOCYTES IN CULTURE | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2023-05-04 | — | — | US | disclosed |
| US-11566229-B2 | Expansion and maintenance of adult primary human hepatocytes in culture | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-01-31 | — | — | US | disclosed |
| US-11319368-B2 | Treatment of hepatotoxicity with IL-11 antibody | SINGAPORE HEALTH SERVICES PTE LTD. (SG) | 2022-05-03 | — | — | US | disclosed |
| EP-3914621-A1 | TREATMENT OF HEPATOTOXICITY | Singapore Health Services Pte. Ltd. (SG) | 2021-12-01 | — | — | EP | disclosed |
| CN-113677706-A | Treatment of hepatotoxicity | 新加坡保健服务私人有限公司 | 2021-11-19 | — | — | CN | disclosed |
| US-20200262910-A1 | TREATMENT OF HEPATOTOXICITY | SINGAPORE HEALTH SERVICES PTE LTD. (SG) | 2020-08-20 | — | — | US | disclosed |
| WO-2020152122-A1 | TREATMENT OF HEPATOTOXICITY | SINGAPORE HEALTH SERVICES PTE. LTD. (SG) | 2020-07-30 | — | — | WO | disclosed |
| US-20200071664-A1 | EXPANSION AND MAINTENANCE OF ADULT PRIMARY HUMAN HEPATOCYTES IN CULTURE | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2020-03-05 | — | — | US | disclosed |
| US-20200069617-A1 | USE OF N-ACETYLCYSTEINE AMIDE IN THE TREATMENT OF ACETAMINOPHEN OVERDOSE | GOLDSTEIN GLENN A (US) | 2020-03-05 | — | — | US | disclosed |
| US-20160326107-A1 | HEPATOPROTECTANT ACETAMINOPHEN MUTUAL PRODRUGS | NEUROGESX, INC. | 2016-11-10 | — | — | US | disclosed |
| US-20110263545-A1 | HEPATOPROTECTANT ACETAMINOPHEN MUTUAL PRODRUGS | ACORDA THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| EP-2285419-A1 | HEPATOPROTECTANT ACETAMINOPHEN MUTUAL PRODRUGS | Neurogesx, Inc. (US) | 2011-02-23 | — | — | EP | disclosed |
| WO-2009143299-A1 | HEPATOPROTECTANT ACETAMINOPHEN MUTUAL PRODRUGS | NEUROGESX, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20070193886-A1 | DETECTION METHODS AND DEVICES | DIONEX CORPORATTION | 2007-08-23 | — | — | US | disclosed |
| WO-2007092331-A2 | DETECTION METHODS AND DEVICES | ESA BIOSCIENCES, INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| WO-2004109279-A2 | SENSITIVE AND SELECTIVE IN VITRO ASSAY FOR THE DETECTION OF REACTIVE DRUG INTERMEDIATES | PFIZER PRODUCTS INC. (US) | 2004-12-16 | — | — | WO | disclosed |
| US-20040248234-A1 | Sensitive and selective in vitro assay for the detection of reactive drug intermediates | PFIZER INC | 2004-12-09 | — | — | US | disclosed |
| US-6719969-B1 | HIGH SPEED HEPATOCYTE PROLIFERATION AND LIVER REGENERATION AFTER INJURY CAUSED BY ACETOMINOPHEN OVERDOSE OR SURGERY; SIDE EFFECT REDUCTION OF GENE THERAPY | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2004-04-13 | — | — | US | disclosed |
| WO-2001010899-A2 | TREATMENT OF LIVER DISEASE AND INJURY WITH CXC CHEMOKINES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326107-A1 | HEPATOPROTECTANT ACETAMINOPHEN MUTUAL PRODRUGS | PTGS1, HPGD, PYGL | PTGS1 1/4885GSTK1 18/4885GLO1 545/4885 |
| US-20110263545-A1 | HEPATOPROTECTANT ACETAMINOPHEN MUTUAL PRODRUGS | PTGS1, HPGD, PYGL | PTGS1 1/4885GSTK1 18/4885GLO1 545/4885 |
| US-20200069617-A1 | USE OF N-ACETYLCYSTEINE AMIDE IN THE TREATMENT OF ACETAMINOPHEN OVERDOSE | AANAT, NAT1, AADAC | PTGS1 251/4885GSTK1 51/4885GLO1 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.